by Daniel Fink, MD, Chair, The Quiet Coalition
As those who follow my writings know, I’m a big believer in the old public health principle that prevention of disease is almost always better and cheaper than treating it. That principle applies to hearing loss. Preserved normal hearing is much better than the best hearing aid, and costs almost nothing–just avoid loud noise or use hearing protection.
But we follow developments in treating or preventing hearing loss caused by noise exposure. The Holy Grail for this research is a drug that people could take after noise exposure, to prevent any lasting auditory consequences. One of these drugs under development is called Ebsalen.
This new report in the peer-reviewed online journal ScienceAdvances discusses repurposing Ebsalen to fight COVID-19 infection.
We think that may be a better use of Ebsalen than its originally intended use.
Dr. Daniel Fink is a leading noise activist based in the Los Angeles area. He is the founding chair of The Quiet Coalition, an organization of science, health, and legal professionals concerned about the impacts of noise on health, environment, learning, productivity, and quality of life in America. Dr Fink also is the interim chair of Quiet Communities’ Health Advisory Council, and he served on the board of the American Tinnitus Association from 2015-2018.